If your estate plan was created before the DNA testing era—or hasn't been updated to account for these new realities—now is ...

Genetic testing company 23andMe, once valued at $6 billion, has filed for bankruptcy. State attorneys general are urging concerned customers to delete their data, while experts warn that state and ...

Regeneron Pharmaceuticals on Monday announced plans to purchase genetic testing company 23andMe for $256 million. The New York-based drugmaker is set to take over 23andMe after winning a bankruptcy ...

New York-based biotech giant Regeneron Pharmaceuticals announced May 19 its plan to purchase the bankrupt genetic testing firm 23andMe in a $256 million deal that could include millions of Americans' ...

At-home DNA kits reveal unknown heirs, sparking inheritance disputes. Estate planners must adapt strategies to protect ...

Drugmaker Regeneron Pharmaceuticals will buy genetic testing firm 23andMe for $256 million through a bankruptcy auction, the companies said Monday. Regeneron said it will comply with 23andMe’s privacy ...

Biotechnology company Regeneron Pharmaceuticals is buying 23andMe for $256 million, two months after the genetic testing company filed for Chapter 11 bankruptcy protection. In March 23andMe said that ...

The Federal Trade Commission is reportedly investigating various direct-to-consumer genetic testing companies, including market giants 23andMe and Ancestry.com, over concerns related to data sharing ...

Bankrupt genetic-testing firm 23andMe agreed to sell its data bank, which once contained DNA samples from about 15 million people, to the drug developer Regeneron Pharmaceuticals for $256 million. The ...

The Food and Drug Administration has issued a severe warning to DIY DNA testing firm 23andMe, telling the company to stop advertising its at-home genetic testing kit that the feds say is misleading, ...

"Long story short, after learning this news, he decided to reach out to his biological father, who turned out to be a local ...